H. Lundbeck A/S
HLUN-A
Rang in aandelen
#2991
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Aandeelprijs
$7.41
Marktkapitalisatie
$6.17B
Verandering (1 dag)
3.44%
Verandering (1 jaar)
33.63%
Land
DK
Handel H. Lundbeck A/S (HLUN-A)
Categorie
Healthcare
EPS voor H. Lundbeck A/S (HLUN-A)
EPS per June 2026 TTM: $0.62
Volgens de laatste financiële rapporten en de aandelenkoers van H. Lundbeck A/S is de huidige EPS van het bedrijf (TTM) $0.62. Eind 2024 had het bedrijf een EPS van $0.44, een stijging ten opzichte van de EPS van 2023 die $0.34 bedroeg.
EPS-geschiedenis van H. Lundbeck A/S van 2004 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $0.62 | 21.73% |
| 2025 | $0.51 | 14.36% |
| 2024 | $0.44 | 29.33% |
| 2023 | $0.34 | 23.11% |
| 2022 | $0.28 | 9.41% |
| 2021 | $0.25 | -80.57% |
| 2020 | $1.31 | -35.12% |
| 2019 | $2.01 | -33.33% |
| 2018 | $3.02 | 41.16% |
| 2017 | $2.14 | 145.59% |
| 2016 | $0.87 | -120.64% |
| 2015 | $-4.22 | 3,227.66% |
| 2014 | $-0.13 | -115.78% |
| 2013 | $0.80 | -23.47% |
| 2012 | $1.05 | -48.14% |
| 2011 | $2.03 | -10.15% |
| 2010 | $2.25 | 14.02% |
| 2009 | $1.98 | -23.91% |
| 2008 | $2.60 | -19.22% |
| 2007 | $3.22 | 78.19% |
| 2006 | $1.81 | -12.40% |
| 2005 | $2.06 | 51.52% |
| 2004 | $1.36 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $2.41 | 288.21% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | -16.24% |
US
|
